The Federal Circuit’s March 19, 2008, decision in Amgen Inc. v. International Trade Commission, No: 2007-1014 (Fed. Cir. 2008), significantly expanded both the ITC’s jurisdiction to conduct investigations and the defenses available to some accused infringers.
This decision, by a split panel, will have important effects on the frequency and scope of Section 337 investigations of alleged patent infringement involving FDA-regulated products.
Read the complete article by clicking on the link below.
Reprinted with permission from Portfolio Media, Inc.
Related Insights
December 11, 2025
Foley Viewpoints
Antitrust Risks and Compliance Strategies in Intellectual Property Portfolio Management
This article analyzes how intellectual property portfolio management can simultaneously promote innovation and present potential…
December 11, 2025
Foley Viewpoints
CARB Releases Proposed Regulations for SB 261 and 253
On December 9, 2025, the California Air Resources Board (CARB) released its proposed regulatory text for the initial regulations…
December 11, 2025
Innovative Technology Insights
OCC Issues Another Crypto-Friendly Interpretive Letter: Permissibility of Riskless Principal Crypto-Assets Transactions
On December 9, 2025, the Office of the Comptroller of the Currency (OCC) issued Interpretive Letter 1188 (IL 1188), confirming that a national bank is permitted, as part of the business of banking, to engage in riskless principal crypto-assets transactions.